Given the huge demands posed by the increasing geriatric population and several chronic diseases and more, including further propelling by the COVID-19 pandemic effects, the pharmaceutical industry in India has witnessed significant growth in the past few years. Given its lower cost production and advanced R&D efficiency, the Indian Pharmaceuticals industry has a prominent role in the global pharmaceuticals industry. India ranks 3rd worldwide for production by volume and 14th by value. The nation is the largest provider of generic medicines globally, occupying a 20 percent share in global supply by volume, and is the leading vaccine manufacturer globally. India also has the highest number of US-FDA compliant Pharma plants outside of US and is home to more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities, as well as a highly skilled resource pool. According to Investindia reports, the pharmaceutical industry in India is currently valued at $50 billion, and is expected to reach $65 billion by 2024 and to $120 billion by 2030. As high economic growth along with increasing penetration of health insurance is expected to push expenditure on healthcare & medicine in India, there are many proficient pharma consultants reviewing this prolific demand for comprehending the pharmaceuticals need from the healthcare and medicine industry.

India Pharma Outlook in this issue presents a list of...